FMRFamide increases the adenylate cyclase activity and cyclic AMP level of molluscan heart

William Joseph Higgins, David A. Price, Michael J. Greenberg

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

FMRFamide (phenylalanyl-methionyl-arginyl-phenylalanine amide) is a cardioexcitatory peptide recently isolated and identified in molluscan ganglia. Both FMRFamide and 5-hydroxytryptamine (5HT), the cardioexcitatory neurotransmitter in molluscs, were tested on the ventricle of the bivalve Mercenaria mercenaria. Both agents increased myocardial contractility, the intracellular cyclic AMP concentration of intact hearts and the adenylate cyclase activity of a myocardial membrane fraction. FMRFamide was 5-10 times more potent than 5HT. All of the effects of 5HT, and none of those of FMRFamide, were blocked by methysergide, a specific 5HT antagonist.

Original languageEnglish (US)
Pages (from-to)425-430
Number of pages6
JournalEuropean Journal of Pharmacology
Volume48
Issue number4
DOIs
StatePublished - Apr 15 1978

Keywords

  • 5-Hydroxytryptamine
  • Adenylate cyclase
  • Cyclic AMP in muscle
  • FMRFamide
  • Methysergide
  • Molluscan heart

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'FMRFamide increases the adenylate cyclase activity and cyclic AMP level of molluscan heart'. Together they form a unique fingerprint.

Cite this